Histogenics Corp. (NASDAQ:HSGX) has earned an average rating of “Buy” from the six research firms that are currently covering the stock. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $7.56.

HSGX has been the subject of several research analyst reports. Needham & Company LLC lifted their price objective on Histogenics Corp. from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 19th. William Blair downgraded Histogenics Corp. from an “outperform” rating to a “market perform” rating in a research report on Wednesday, September 7th. BTIG Research upgraded Histogenics Corp. from a “neutral” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Thursday, August 11th. Finally, Zacks Investment Research upgraded Histogenics Corp. from a “hold” rating to a “buy” rating and set a $3.25 price objective for the company in a research report on Friday, August 26th.

Histogenics Corp. (NASDAQ:HSGX) traded down 3.92% during trading on Wednesday, hitting $2.94. The company had a trading volume of 7,570 shares. The company’s market capitalization is $39.02 million. Histogenics Corp. has a 12-month low of $1.39 and a 12-month high of $4.97. The firm has a 50-day moving average of $3.20 and a 200 day moving average of $2.36.

Histogenics Corp. (NASDAQ:HSGX) last issued its quarterly earnings data on Thursday, August 11th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by $0.01. During the same quarter in the previous year, the company posted ($0.58) earnings per share. On average, equities research analysts forecast that Histogenics Corp. will post ($2.11) earnings per share for the current year.

In other news, major shareholder Split Rock Partners Ii, Lp bought 276,801 shares of the company’s stock in a transaction dated Thursday, September 29th. The stock was bought at an average price of $2.25 per share, for a total transaction of $622,802.25. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 16.80% of the company’s stock.

An institutional investor recently raised its position in Histogenics Corp. stock. Carl Domino Inc increased its position in shares of Histogenics Corp. (NASDAQ:HSGX) by 24.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 34,011 shares of the company’s stock after buying an additional 6,700 shares during the period. Carl Domino Inc owned approximately 0.26% of Histogenics Corp. worth $110,000 as of its most recent SEC filing. 32.30% of the stock is owned by institutional investors and hedge funds.

Histogenics Corp. Company Profile

Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

5 Day Chart for NASDAQ:HSGX

Receive News & Stock Ratings for Histogenics Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corp. and related stocks with our FREE daily email newsletter.